Yes. As of September 2026, Abbott Laboratories (ABT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.0% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.94% / 30% · Interest income / Revenue 0.41% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 17.0% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.34% / 33% · Receivables / Mkt Cap (36m) 4.92% / 49% · Interest income / Revenue 0.41% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 17.0% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.34% / 33.33% · Receivables / Mkt Cap (24m) 4.92% / 33.33% · Interest income / Revenue 0.41% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 27.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.30% / 33.33% · Receivables / Avg Assets (4Q) 8.15% / 33.33% · Interest income / Revenue 0.41% / 5% | Pass |
| FTSE | Debt / Total Assets 28.8% / 33.33% · (Cash+ST Inv) / Total Assets 3.97% / 33.33% · (Cash+Recv) / Total Assets 12.3% / 33.33% · Interest income / Revenue 0.41% / 5% | Pass |
Yes. As of September 2026, Abbott Laboratories (ABT) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Abbott Laboratories is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.41% of each dividend: Abbott Laboratories's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Abbott Laboratories (NYSE: ABT) is a Healthcare company (Medical - Devices) with a market capitalization of $186.1B. The Maz Rating grades it against the other companies in its sector.
Abbott Laboratories's current Maz Rating and its five factor grades are for members: log in to see them.
At $107.45, Abbott Laboratories trades at 40.2x trailing earnings, 3.9x sales and 3.7x book value, with an EV/EBITDA of 19.4. Over the last twelve months it generated about $47.8B of revenue and $4.6B of net income. It runs a gross margin of 57.0%, an operating margin of 15.0% and a net margin of 9.7%. It shows return on equity of 9.1%, return on invested capital of 5.5% and a free cash flow yield of 3.6%. On the balance sheet: a debt-to-equity ratio of 0.61 and a current ratio of 1.45. Over the past 52 weeks the share price ranged from $81.97 to $132.03, with a beta of 0.54.
Abbott Laboratories pays a dividend yielding 2.32%, with 92% of earnings paid out. Its Maz Dividend Score is 2.83 out of 5, ranked against the other dividend payers in its sector (Safety 1.70, Growth 3.70, Yield 3.90, Consistency 3.68).
43 Wall Street analyst ratings cover the stock: 33 Buy and 10 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.